liposomal disintegrin

Liposomal disintegrin is an investigational anti-tumor therapeutic being developed by Molecular Express. It consists of a disintegrin—a potent, non-enzymatic protein typically derived from snake venom—encapsulated within a liposomal delivery vehicle. Disintegrins are characterized by their ability to bind specifically to integrins, such as alpha-V/beta-3 (αvβ3), alpha-V/beta-5 (αvβ5), and alpha-5/beta-1 (α5β1), which are often overexpressed on the surface of many cancer cells and the endothelial cells of tumor-associated blood vessels. By competitively inhibiting these integrins, the drug disrupts cell-extracellular matrix interactions, thereby blocking cell adhesion, migration, and tumor-induced angiogenesis. The liposomal formulation is designed to improve the pharmacokinetics, stability, and targeted delivery of the disintegrin peptide to the tumor microenvironment, potentially reducing systemic toxicity while enhancing efficacy.

Other names

Liposomal Disintegrin: A Novel and Effective Anti-Tumor Agent